New-onset toxicity with programmed death-1 inhibitor rechallenge

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immunotherapy, including cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, is a primary treatment for metastatic melanoma.
• PD-1 inhibitors generally have a better safety profile and fewer adverse effects than CTLA-4 inhibitors.

Observation:

• Sequential administration of immunotherapies, particularly CTLA-4 inhibitors followed by PD-1 inhibitors, may heighten the risk of severe immune-mediated adverse reactions.
• Rechallenging with the same or similar drug class after severe (grade 3 or 4) adverse events requires caution due to potential toxicity re-emergence or new severe effects.

Findings:

• This article details a case of fatal immune-related hepatotoxicity in a patient who received a CTLA-4 inhibitor followed by a PD-1 inhibitor.
• The case highlights the potential for severe, unexpected adverse events even with newer, better-tolerated agents.

Implications:

• Understanding the safety profiles and mechanisms of action of CTLA-4 and PD-1 inhibitors is crucial for optimizing treatment sequencing and managing adverse events in melanoma patients.
• Careful patient monitoring and risk-benefit assessment are essential when using sequential immunotherapies to mitigate potentially life-threatening toxicities.